|
Date Submitted:
12/11/07
Hits: 6 Rating:  0/5 based on 0 votes
Targeted Cancer Therapies Continue to Impress
Description:
SATURDAY, June 2 (HealthDay News) -- Small scientific steps are making headway against various cancers, many of which are historically difficult to treat.
Two much-watched drugs of the past year, Sprycel and Avastin, are again showing good results in new trials, according to research presented Saturday at the American Society of Clinical Oncology (ASCO) annual meeting, in Chicago. "Molecular targeted therapies that were developed a few years ago are being expanded dramatically in scope," said Dr. Robert F. Ozols, senior vice president of the medical science division at Fox Chase Cancer Center in Philadelphia and chairman of ASCO's communications committee. "These are incremental advances, but they're important," added Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society. "I don't see anything in the plenary session or any other special session that stands out as a major breakthrough. We've come to a time when these advances are becoming routine, an Read the Complete Article Similar content: '69 New York Jets Continue Their Winning Ways, in Arthritis Therapies for Diabetes: Pramlintide and Exenatide, in Diabetes Do Alternative Therapies Work for Epilepsy?, in Epilepsy Cellular Therapies for Treating Heart Disease to Make an Impact by the End of the Decade , in Heart Disease Prostate Cancer Gene Also Raises Colon Cancer Risk, in Prostate Cancer |
